| P2093 | author name string | Roger J Hajjar | |
| | Yoshiaki Kawase | |
| | Hung Q Ly | |
| P2860 | cites work | Unchanged Protein Levels of SERCA II and Phospholamban but Reduced Ca 2+ Uptake and Ca 2+ -ATPase Activity of Cardiac Sarcoplasmic Reticulum From Dilated Cardiomyopathy Patients Compared With Patients With Nonfailing Hearts | Q71807622 |
| | Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium | Q72092902 |
| | Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium | Q72133115 |
| | Gene therapy for cardiovascular disease | Q72369189 |
| | Heart failure | Q73397364 |
| | The future of gene therapy | Q73741937 |
| | Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia | Q73824966 |
| | Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts | Q75294807 |
| | Age-associated alterations in calcium current and its modulation in cardiac myocytes | Q77306755 |
| | Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia | Q78019724 |
| | Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy | Q78494932 |
| | Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a | Q22010899 |
| | Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q22306347 |
| | Ca2+-ATPases in non-failing and failing heart: evidence for a novel cardiac sarco/endoplasmic reticulum Ca2+-ATPase 2 isoform (SERCA2c) | Q24300590 |
| | A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. | Q24301857 |
| | Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics | Q28141424 |
| | Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 |
| | LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 |
| | Gutless adenovirus: last-generation adenovirus for gene therapy | Q28277560 |
| | Cardiac adenoviral S100A1 gene delivery rescues failing myocardium | Q28296403 |
| | Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | Q28354203 |
| | PKC-alpha regulates cardiac contractility and propensity toward heart failure | Q28589911 |
| | In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 |
| | Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 |
| | Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results | Q31767833 |
| | Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium | Q31952673 |
| | Adeno-associated virus serotypes: vector toolkit for human gene therapy | Q33249130 |
| | Regulated gene expression systems | Q33837136 |
| | AAV vectors: is clinical success on the horizon? | Q33840994 |
| | Gene therapy: designer promoters for tumour targeting | Q33870806 |
| | Prospects for gene therapy for heart failure | Q33881236 |
| | Gene transfer: from concept to therapy | Q33914117 |
| | Decreased efficiency of adenovirus-mediated gene transfer in aging cardiomyocytes | Q34074815 |
| | Targeting phospholamban by gene transfer in human heart failure | Q34074819 |
| | Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban | Q34180320 |
| | Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade | Q34191737 |
| | Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure | Q34241246 |
| | Nonviral vectors in the new millennium: delivery barriers in gene transfer | Q34270234 |
| | Type 1 phosphatase, a negative regulator of cardiac function | Q34281889 |
| | Assessment of risks associated with cardiovascular gene therapy in human subjects | Q34353818 |
| | Tissue specific promoters in targeting systemically delivered gene therapy. | Q34375985 |
| | Seven-transmembrane-spanning receptors and heart function | Q34503394 |
| | Myocardial gene therapy | Q34503413 |
| | Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. | Q34542759 |
| | Opportunities for the use of lentiviral vectors in human gene therapy | Q34561988 |
| | VEGF gene delivery for treatment of ischemic cardiovascular disease | Q34635640 |
| | Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure | Q34978011 |
| | Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. | Q35025591 |
| | Targeting calcium cycling proteins in heart failure through gene transfer | Q35037546 |
| | Ca(2+)-handling proteins and heart failure: novel molecular targets? | Q35100348 |
| | Genetic, cellular and immune approaches to disease therapy: past and future | Q35647868 |
| | Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation | Q35749168 |
| | Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins | Q35933316 |
| | Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart--gene therapy | Q36017229 |
| | Modulation of ventricular function through gene transfer in vivo | Q36067860 |
| | Targeting survival signaling in heart failure | Q36076192 |
| | Gene transfer for ischemic cardiovascular disease: is this the end of the beginning or the beginning of the end? | Q36304278 |
| | Chronic heart failure: an overview of conventional treatment versus novel approaches | Q36321764 |
| | Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. | Q36441343 |
| | Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro. | Q36548752 |
| | Lentiviral vectors for gene therapy of heart disease. | Q36724915 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice | Q36735680 |
| | Gene therapy in the treatment of heart failure | Q36786243 |
| | Targeting myocardial beta-adrenergic receptor signaling and calcium cycling for heart failure gene therapy | Q36865884 |
| | Calcium and cardiomyopathies. | Q37056467 |
| | Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling | Q37682472 |
| | 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. | Q40655750 |
| | A stable system for the high-titer production of multiply attenuated lentiviral vectors | Q40860697 |
| | Gene transfer by adeno-associated virus vectors into the central nervous system | Q41450710 |
| | In vivo gene transfer: a biological tool | Q41500672 |
| | Development of a novel perfusion technique to allow targeted delivery of gene therapy--the V-Focus system. | Q42184457 |
| | Vigilant vector: heart-specific promoter in an adeno-associated virus vector for cardioprotection | Q42518357 |
| | Effects of adeno-associated virus DNA hairpin structure on recombination | Q42755152 |
| | Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure | Q43726347 |
| | How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures? | Q43727635 |
| | The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells | Q43792049 |
| | Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy | Q43935483 |
| | New efficient catheter-based system for myocardial gene delivery | Q44160786 |
| | Functional consequences of Na/Ca exchanger overexpression in cardiac myocytes. | Q44262665 |
| | Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain | Q44686125 |
| | SERCA2A overexpression decreases the incidence of aftercontractions in adult rabbit ventricular myocytes | Q45142538 |
| | Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo | Q45413958 |
| | Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart | Q45507049 |
| | Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo | Q45709105 |
| | Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity | Q45762593 |
| | In vivo gene transfection of human endothelial cell nitric oxide synthase in cardiomyocytes causes apoptosis-like cell death. Identification using Sendai virus-coated liposomes | Q45762805 |
| | Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. | Q45855123 |
| | Gene delivery to the myocardium by intrapericardial injection. | Q45862161 |
| | Transgenic rat hearts overexpressing SERCA2a show improved contractility under baseline conditions and pressure overload | Q45864600 |
| | Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models | Q45865257 |
| | Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins | Q45865601 |
| | Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus | Q45867102 |
| | Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals | Q45869517 |
| | Nonviral strategies for gene therapy | Q45881959 |
| | Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer | Q45887681 |
| | Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 |
| | Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. | Q46636022 |
| | Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer | Q46964433 |
| | Efficient gene transfer into myocardium by direct injection of adenovirus vectors | Q64377591 |
| | Adenovirus-catheter compatibility increases gene expression after delivery to porcine myocardium | Q64377941 |
| | Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function | Q64378835 |
| | Breaking the barriers to global gene delivery | Q64378872 |
| | Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1 | Q64378890 |
| | Efficient and selective adenovirus-mediated gene transfer into vascular neointima | Q64383680 |
| | Function of the sarcoplasmic reticulum and expression of its Ca2(+)-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat | Q68409187 |
| | Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium | Q70526590 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 127-136 | |
| P577 | publication date | 2008-05-29 | |
| P1433 | published in | Journal of Cardiovascular Translational Research | Q6294906 |
| P1476 | title | Advances in gene-based therapy for heart failure | |
| P478 | volume | 1 | |